Rapid, Structure-Based Exploration of Pipecolic Acid Amides as Novel Selective Antagonists of the FK506-Binding Protein 51
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
The FK506-binding protein 51 (FKBP51) is a key regulator of stress hormone receptors and an established risk factor for stress-related disorders. Drug development for FKBP51 has been impaired by the structurally similar but functionally opposing homologue FKBP52. High selectivity between FKBP51 and FKBP52 can be achieved by ligands that stabilize a recently discovered FKBP51-favoring conformation. However, drug-like parameters for these ligands remained unfavorable. In the present study, we replaced the potentially labile pipecolic ester group of previous FKBP51 ligands by various low molecular weight amides. This resulted in the first series of pipecolic acid amides, which had much lower molecular weights without affecting FKBP51 selectivity. We discovered a geminally substituted cyclopentyl amide as a preferred FKBP51-binding motif and elucidated its binding mode to provide a new lead structure for future drug optimization.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gene–Stress–Epigenetic regulation of FKBP5: clinical and translational implications
Zannas, A. S., Wiechmann, T., Gassen, N. C., & Binder, E. B. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2015.235 · Cited by 622
FKBP51 and FKBP52 in signaling and disease
Storer, C. L., Dickey, C. A., Galigniana, M. D., Rein, T., & Cox, M. B. (2011) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2011.08.001 · Cited by 266
Sinars, C. R., Cheung-Flynn, J., Rimerman, R. A., Scammell, J. G., Smith, D. F., & Clardy, J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0231020100 · Cited by 254
Selective inhibitors of the FK506-binding protein 51 by induced fit
Gaali, S., Kirschner, A., Cuboni, S., Hartmann, J., Kozany, C., Balsevich, G., Namendorf, C., Fernandez-Vizarra, P., Sippel, C., Zannas, A. S., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1699 · Cited by 245
Self-citationWu, B., Li, P., Liu, Y., Lou, Z., Ding, Y., Shu, C., Ye, S., Bartlam, M., Shen, B., & Rao, Z. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0305969101 · Cited by 165
Large FK506-binding proteins shape the pharmacology of rapamycin
März, A. M., Fabian, A.-K., Kozany, C., Bracher, A., & Hausch, F. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.00678-12 · Cited by 141
Self-citationPharmacological Inhibition of the Psychiatric Risk Factor FKBP51 Has Anxiolytic Properties
Hartmann, J., Wagner, K. V., Gaali, S., Kirschner, A., Kozany, C., Ruhter, G., Dedic, N., Hausl, A. S., Hoeijmakers, L., Westerholz, S., et al. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.4024-14.2015 · Cited by 109
Self-citationThe prospect of FKBP51 as a drug target
Schmidt, M. V., Paez‐Pereda, M., Holsboer, F., & Hausch, F. (2012) · ChemMedChem · doi:10.1002/cmdc.201200137 · Cited by 99
Self-citationFluorescent Probes to Characterise FK506‐Binding Proteins
Kozany, C., März, A., Kress, C., & Hausch, F. (2009) · ChemBioChem · doi:10.1002/cbic.200800806 · Cited by 91
Evaluation of synthetic FK506 analogues as ligands for the FK506-binding proteins 51 and 52
Gopalakrishnan, R., Kozany, C., Gaali, S., Kress, C., Hoogeland, B., Bracher, A., & Hausch, F. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201746x · Cited by 64
Self-citationStructural characterization of the PPIase domain of FKBP51, a cochaperone of human Hsp90
Bracher, A., Kozany, C., Thost, A.-K., & Hausch, F. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444911013862 · Cited by 62
Self-citationIncreasing the efficiency of ligands for FK506-binding protein 51 by conformational control
Wang, Y., Kirschner, A., Fabian, A.-K., Gopalakrishnan, R., Kress, C., Hoogeland, B., Koch, U., Kozany, C., Bracher, A., & Hausch, F. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400087k · Cited by 60
Self-citationExploration of pipecolate sulfonamides as binders of the FK506-binding proteins 51 and 52
Gopalakrishnan, R., Kozany, C., Wang, Y., Schneider, S., Hoogeland, B., Bracher, A., & Hausch, F. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201747c · Cited by 52
Bracher, A., Kozany, C., Hähle, A., Wild, P., Zacharias, M., & Hausch, F. (2013) · Journal of Molecular Biology · doi:10.1016/j.jmb.2013.07.041 · Cited by 45
Self-citationMustafi, S. M., LeMaster, D. M., & Hernández, G. (2014) · Biochemical Journal · doi:10.1042/bj20140232 · Cited by 25
Recent Progress in FKBP Ligand Development
Feng, X., Pomplun, S., & Hausch, F. (2015) · Current Molecular Pharmacology · doi:10.2174/1874467208666150519113313 · Cited by 22
Self-citation
Cited by
FKBP Ligands—Where We Are and Where to Go?
Kolos, J. M., Voll, A. M., Bauder, M., & Hausch, F. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01425 · Cited by 158
“focused on the substitution of the top group part of the SAFit ligands by using a solid-phase synthesis strategy (Gaali et al., 2016).”
MethodSelf-citationHähle, A., Merz, S., Meyners, C., & Hausch, F. (2019) · Biomolecules · doi:10.3390/biom9010035 · Cited by 119
Self-citationStructure-Based Design of High-Affinity Macrocyclic FKBP51 Inhibitors
Bauder, M., Meyners, C., Purder, P. L., Merz, S., Sugiarto, W. O., Voll, A. M., Heymann, T., & Hausch, F. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c02195 · Cited by 53
Self-citationFKBP51 and FKBP52 regulate androgen receptor dimerization and proliferation in prostate cancer cells
Maeda, K., Habara, M., Kawaguchi, M., Matsumoto, H., Hanaki, S., Masaki, T., Sato, Y., Matsuyama, H., Kunieda, K., Nakagawa, H., et al. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13030 · Cited by 32
Metadata
- Authors
- Gaali, S., Feng, X., Hähle, A., Sippel, C., Bracher, A., & Hausch, F.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2016-03-08
- Volume
- 59
- Issue
- 6
- Pages
- 2410-2422
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2293815880
- Cited by
- 37
- References
- 16
- FWCI
- 2.56
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.